Lysogene Reports Its Cash Position as of 31 March 2020

• Cash and cash equivalent of €29.9 million¹ as of 31 March 2020

PARIS–(BUSINESS WIRE)–Regulatory News:

Lysogene (Paris:LYS) (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today reports its cash position as of 31 March 2020.

As of 31 March 2020, cash and cash equivalents amounted to €29.9 million¹ (compared to €26.5 million as of 31 December 2019). This amount includes the €7.7m gross proceeds from the capital increase led in March 2020 by top-tier Pharma investor OrbiMed and Lysogene shareholder and partner Sarepta.